Industry News Sellas Life Sciences BioSpace

Sellas' GPS vaccine clears Phase 3 REGAL in AML, with an accelerated-approval talk next

  • Phase 3 REGAL randomized 126 AML patients in second or later remission to galinpepimut-S maintenance or investigator's-choice best available therapy.
  • Median overall survival was 24 months versus 14.7 months, a 41% lower risk of death, described as statistically significant; hazard ratio and p-value were not given.
  • Safety was mostly mild injection-site reactions. Sellas will meet the FDA about accelerated approval, with a filing planned for the first half of next year.
Points Based on public reports

Read this against the company's own history: this trial was long expected to miss, so the first thing to test is how the final analysis was triggered and whether the open-label design and a small event count flatter the result. A 9-month median gain against best available therapy is large for a vaccine, but without a hazard ratio, confidence interval or secondary endpoints, regulators will be the real judge. The comparator, a mixed best-available arm, is the weak spot to watch at the conference data.